Bionevia

BioNevia LLC is a clinical-stage biotechnology company dedicated to developing drugs for the treatment of diabetes-related diseases. The company's lead compound, BNV-222, is a potential first-in-class disease-modifying therapeutic designed to slow or halt diabetic peripheral neuropathy (DPN), a progressive and debilitating complication of diabetes. Based on its mechanism of action, BNV-222 also has the potential to effectively treat other diabetes complications, such as nephropathy and retinopathy.